Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Screening for Trisomies by cfDNA Testing of Maternal Blood in Twin Pregnancy

Update of the Fetal Medicine Foundation Results and Meta-analysis

Gil, M. M.; Galeva, S.; Jani, J.; Konstantinidou, L.; Akolekar, R.; Plana, M. N.; Nicolaides, K. H.

Obstetrical & Gynecological Survey: November 2019 - Volume 74 - Issue 11 - p 627–629
doi: 10.1097/OGX.0000000000000740

(Abstracted from Ultrasound Obstet Gynecol 2019;53:734–742)

Cell-free DNA (cfDNA) analysis of maternal blood is useful and effective when screening for trisomies 21, 18, and 13 in singleton pregnancies. However, in twin pregnancies, data on cfDNA tests are much more limited: in a previous literature review and meta-analysis, there were only 5 prospective studies.

Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom (M.M.G., S.G., L.K., K.H.N.); Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz (M.M.G.); School of Health Sciences, Universidad Francisco de Vitoria, Pozuelo de Alarcón (M.M.G.), Madrid, Spain; Department of Fetal Medicine, Medway Maritime Hospital, Gillingham, United Kingdom (S.G., R.A.); Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium (J.J.); Institute of Medical Sciences, Canterbury Christ Church University, Chatham, United Kingdom (R.A.); Department of Preventive Medicine and Public Health, Hospital Príncipe de Asturias, Alcalá de Henares (M.N.P.); and CIBER Epidemiology and Public Health (CIBERESP) (M.N.P.), Madrid, Spain

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.